A Phase 1 Study to Evaluate the Safety and Effects of a Single Dose of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Adults.
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HCXT-2001 Tablets and HCXT-2001 Tablets(A) After Single Administration in Healthy Adult Participants.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Laura E Elliot, MBCHb
- Numéro de téléphone: +64 9 242 3321
- E-mail: laura.elliott@momcr.co.nz
Lieux d'étude
-
-
Auckland
-
Takapuna, Auckland, Nouvelle-Zélande, 0622
- Momentum Clinical Research (MCR)
-
Contact:
- Laura E Elliot, MBCHb
- Numéro de téléphone: +64 9 242 3321
- E-mail: laura.elliott@momcr.co.nz
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
La description
Inclusion Criteria:
- Body weight ≥ 50 kg for males and ≥ 45 kg for females, and body mass index (BMI) between 18.0 and 30.0 kg/m2 (inclusive) at screening.
- In good general health as determined by medical history, vital signs, physical examination, 12-lead ECG, laboratory tests (including hematology, blood biochemistry, coagulation function tests, urinalysis, stool routine tests), chest X-ray, etc., with results either within normal limits or assessed by the investigator as not clinically significant.
- Has been fully informed about the study, voluntarily agrees to participate, and has signed the ICF.
- The participant and their sexual partner(s) have no plans for conception from 2 weeks before screening until 6 months after the last dose of the investigational product, and agree to voluntarily using one or more highly effective non-pharmacological contraceptive methods and no intention of donating sperm or eggs during this period.
Exclusion Criteria:
- History or presence of immunological diseases.
- Women who are pregnant or are breastfeeding.
- Any prior or current disease or abnormality that, in the investigator's judgment, is clinically significant and may interfere with the conduct or interpretation of the study, including but not limited to neurological, cardiovascular, renal, hepatic, gastrointestinal, respiratory, hematological, endocrine, oncologic, pulmonary, immunological, psychiatric, or cerebrovascular conditions.
- Individuals who smoked, consumed coffee, St. John's Wort (hypericum perforatum), grapefruit, pomelo juice, or cranberry juice, and/or engagement in strenuous physical activity within 24 hours prior to dosing, which in the opinion of the investigator may affect drug absorption, distribution, metabolism, or excretion.
- Suspected or known allergy to any component of the investigational product, or any documented history of allergies
- Previous surgical procedures that may affect the results of the clinical study or gastric/abdominal surgery that may impact oral drug absorption; or recent major gastric/abdominal surgery of any kind within 12 weeks prior to screening or during study. With the exception of minor surgeries that in the opinion of the investigator/medical monitor, such as excision of subcutaneous lipomas.
- Having taken any prescription medication, over-the-counter drug, herbal medicine, or dietary supplement within 14 days prior to dosing or within five half-lives of the first administration, except for the condition without impact on the study outcomes as determined by the investigator. Occasional paracetamol less than 1000 mg for minor ailments is permitted if required.
- Non-physiological blood loss or donation of more than 400 mL of blood within 2 months prior to screening, receipt of a blood transfusion within 2 months prior to screening; or plans to donate blood during the study or within 60 days after the last dose.
- Participation in any investigational drug or medical device clinical trial with administration of the investigational product or device intervention within 3 months or five half-lives prior to screening.
- History of alcohol abuse, or consumption of more than 14 alcohol units per week within 6 months prior to screening , or unwillingness to abstain from alcohol during the study, or a positive alcohol test at screening.
- History of smoking (average daily cigarette consumption ≥ 5 cigarettes within 3 months prior to screening) or unwillingness to abstain from smoking during the study.
- History of drug abuse, use of illicit drugs within 3 months prior to the study, or a positive urine drug screen.
- Infection (including chronic or localized infection) within 7 days prior to screening, or a history of recurrent infections with underlying conditions predisposing to infections, or a history of opportunistic infections.
- Positive test result for any of the following: hepatitis B surface antigen, syphilis-specific antibody, hepatitis C antibody, or human immunodeficiency virus antibody.
- Those who have received any vaccine within 1 month prior to screening, or who are scheduled to receive any vaccine during the study or within 1 month after study completion.
- Having any other factors that, in the opinion of the investigator, may affect the study results or interfere with the participant's participation in the clinical study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Quadruple
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: HCXT-2001 Tablets - Cohort 1
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Expérimental: HCXT-2001 Tablets - Cohort 2
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Comparateur placebo: HCXT-2001 Tablets - Placebo Cohort 1
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Expérimental: HCXT-2001 Tablets(A) - Cohort 3
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Expérimental: HCXT-2001 Tablets(A) - Cohort 4
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Comparateur placebo: HCXT-2001 Tablets(A) - Placebo Cohort 3
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Comparateur placebo: HCXT-2001 Tablets - Placebo Cohort 2
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Comparateur placebo: HCXT-2001 Tablets(A) - Placebo Cohort 4
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Number of participants with AEs,SEAs, with abnormal - vital signs,physcial examinations,clinical laboratory results ,12-lead ECGs and stool routine tests
Délai: Day 1 to Day 50
|
Day 1 to Day 50
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Maximum concentration of the drug (Cmax) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Délai: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Time to maximum concentration (Tmax) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Délai: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Area under the plasma concentration-time curve (AUC, including AUC0-t and AUC0-inf, etc.) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Délai: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Apparent volume of distribution (Vd/F) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Délai: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Apparent clearance (CL/F) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A)
Délai: Day 1 to day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to day 50
|
|
Plasma elimination half-life (t1/2) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Délai: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Mean residence time (MRT) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Délai: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Anti-drug antibodies (ADAs) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Délai: Day 1 to Day 50
|
Day 1 to Day 50
|
|
|
Neutralizing antibodies (Nabs) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Délai: Day 1 to Day 50
|
Day 1 to Day 50
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- HCXT-2001-PS-1-02
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .